Cargando…

Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database

BACKGROUND: This study examined demographics, comorbidities and healthcare resource use (HCRU) and costs among Japanese patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). METHODS: We conducted a repeated cross-sectional analysis of the Medical Data Vision...

Descripción completa

Detalles Bibliográficos
Autores principales:	Terai, Shuji, Buchanan-Hughes, Amy, Ng, Alvin, Lee, I-Heng, Hasegawa, Ken
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2021
Materias:	Original Article—Liver, Pancreas, and Biliary Tract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7932941/ https://www.ncbi.nlm.nih.gov/pubmed/33496858 http://dx.doi.org/10.1007/s00535-021-01759-2

Ejemplares similares

Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases
por: Wong, Robert J., et al.
Publicado: (2021)

Bofutsushosan, a Japanese herbal (Kampo) medicine, attenuates progression of nonalcoholic steatohepatitis in mice
por: Ono, Masafumi, et al.
Publicado: (2013)

Effect of miglitol on the suppression of nonalcoholic steatohepatitis development and improvement of the gut environment in a rodent model
por: Kishida, Yumi, et al.
Publicado: (2017)

Noninvasive approach to indicate risk factors of nonalcoholic steatohepatitis overlapping autoimmune hepatitis based on peripheral lymphocyte pattern
por: Kado, Akira, et al.
Publicado: (2023)

Serum metabolomic profile and potential biomarkers for severity of fibrosis in nonalcoholic fatty liver disease
por: Tokushige, Katsutoshi, et al.
Publicado: (2013)

Systemic inflammation as fuel for acute liver injury in COVID-19
por: Effenberger, Maria, et al.
Publicado: (2021)

Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19
por: Campos-Murguía, Alejandro, et al.
Publicado: (2021)

Hepatocellular liver injury in hospitalized patients affected by COVID-19: Presence of different risk factors at different time points
por: Leo, M., et al.
Publicado: (2022)

Clinical update on risks and efficacy of anti-SARS-CoV-2 vaccines in patients with autoimmune hepatitis and summary of reports on post-vaccination liver injury
por: Lleo, Ana, et al.
Publicado: (2022)

Chronic liver disease-related mortality in diabetes before and during the COVID-19 in the United States
por: Kim, Donghee, et al.
Publicado: (2023)

Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis: A prospective single center study
por: Iavarone, Massimo, et al.
Publicado: (2023)

COVID-19 vaccination among cirrhotics in Italy: High coverage and effectiveness of 3 doses versus 2 in preventing breakthrough infection and hospitalization
por: Stroffolini, Tommaso, et al.
Publicado: (2023)

Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis
por: Sayiner, Mehmet, et al.
Publicado: (2017)

Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan
por: Yoneda, Masato, et al.
Publicado: (2021)

CHD is Associated With Higher Grades of NAFLD Predicted by Liver Stiffness
por: Song, Yan, et al.
Publicado: (2020)

Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis
por: Sakaida, Isao, et al.
Publicado: (2016)

Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study)
por: Sakaida, Isao, et al.
Publicado: (2020)

Systematic review and meta-analysis: analysis of variables influencing the interpretation of clinical trial results in NAFLD
por: Ampuero, Javier, et al.
Publicado: (2022)

Mass Spectrometry-Based (GeLC-MS/MS) Comparative Proteomic Analysis of Endoscopically (ePFT) Collected Pancreatic and Gastroduodenal Fluids
por: Paulo, Joao A, et al.
Publicado: (2012)

Dramatic Survival Benefit Related to R0 Resection of Pancreatic Adenocarcinoma in Patients With Tumor ≤25 mm in Size and ≤1 Involved Lymph Nodes
por: Tummala, Pavan, et al.
Publicado: (2013)

A Pilot Study to Develop a Diagnostic Test for Pancreatic Ductal Adenocarcinoma Based on Differential Expression of Select miRNA in Plasma and Bile
por: Cote, Gregory A, et al.
Publicado: (2014)

Hepatic IRS1 and ß-catenin expression is associated with histological progression and overt diabetes emergence in NAFLD patients
por: Enooku, Kenichiro, et al.
Publicado: (2018)

Blockade of C5aR1 alleviates liver inflammation and fibrosis in a mouse model of NASH by regulating TLR4 signaling and macrophage polarization
por: Jiang, Keqing, et al.
Publicado: (2023)

Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience
por: Waldenström, Jesper, et al.
Publicado: (2016)

Transition in the etiology of liver cirrhosis in Japan: a nationwide survey
por: Enomoto, Hirayuki, et al.
Publicado: (2019)

LKB1 Haploinsufficiency Cooperates With Kras to Promote Pancreatic Cancer Through Suppression of p21-Dependent Growth Arrest
por: Morton, Jennifer P., et al.
Publicado: (2010)

Cholecystectomy or Gallbladder In Situ After Endoscopic Sphincterotomy and Bile Duct Stone Removal in Chinese Patients
por: Lau, James Y.W., et al.
Publicado: (2006)

Liver Sinusoidal Endothelial Cell Lectin, LSECtin, Negatively Regulates Hepatic T-Cell Immune Response
por: Tang, Li, et al.
Publicado: (2009)

Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan
por: Tateishi, Ryosuke, et al.
Publicado: (2021)

The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan
por: Enomoto, Hirayuki, et al.
Publicado: (2020)

Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan
por: Sakakida, Tomoki, et al.
Publicado: (2023)

A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update
por: Tateishi, Ryosuke, et al.
Publicado: (2018)

Development of performance indicators for hepatitis countermeasures as a tool for the assessment and promotion of liver cancer prevention in Japan
por: Shimakami, Tetsuro, et al.
Publicado: (2023)

Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan
por: Aoki, Taku, et al.
Publicado: (2014)

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
por: Kobayashi, Masahiro, et al.
Publicado: (2019)

Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study
por: Hayashi, Norio, et al.
Publicado: (2013)

Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Drescher, Hannah K., et al.
Publicado: (2019)

Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan
por: Sakaida, Isao, et al.
Publicado: (2015)

Standard versus delayed initiation of S-1 adjuvant chemotherapy after surgery for pancreatic cancer: a secondary analysis of a nationwide cohort by the Japan Pancreas Society
por: Tomimaru, Yoshito, et al.
Publicado: (2023)

Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus
por: Tahata, Yuki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f3blttlanmdhlbaum81ca53qiv